Identification of genes in HepG2 cells that respond to DNA methylation and histone deacetylation inhibitor treatment

Sun,Qiang; Xie,Yu; Wang,Guojing; Li,Jidong

doi:10.3892/etm.2014.1789

Identification of genes in HepG2 cells that respond to DNA methylation and histone deacetylation inhibitor treatment

Authors:
- Qiang Sun
- Yu Xie
- Guojing Wang
- Jidong Li
View Affiliations

Affiliations: General Surgery Department, The Second Artillery General Hospital of PLA, Beijing 100088, P.R. China, Surgical Oncology Department, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: June 18, 2014 https://doi.org/10.3892/etm.2014.1789
Pages: 813-817

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that epigenetics has an important role in the regulation of gene expression in cancer. Epigenetics is the study of reversible, heritable changes in gene function, which occur independently from changes in the DNA sequence. DNA methylation and histone deacetylation are the two most important epigenetic modifications. DNA methylation was one of the first discovered epigenetic modifications and it may lead to changes in chromatin structure, DNA conformation and DNA stability, thereby controlling gene expression. Sample data on the HepG2 cell line from the Gene Expression Omnibus database under GSE5230 accession number were obtained and GEOquery and the limma package were then used to analyze the data and identify differentially expressed genes using Gene Otology. This was conducted in order to investigate the effect on gene expression of inhibiting DNA methylation and histone deacetylation, and to explore the potential role of epigenetics in the development and treatment of hepatic carcinoma. It was found that inhibition of DNA methylation and histone deacetylation affected not only substance metabolism, but also the immune activity in HepG2 cells. Furthermore, common target sites for transcription factors were identified in the differentially expressed genes. It may be concluded that the inhibition of DNA methylation and histone deacetylation contributes to the treatment of hepatic carcinoma and may provide a novel therapeutic strategy for the treatment of hepatic cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Chen JG, Zhang SW and Chen WQ: Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004–2005. Zhonghua Yu Fang Yi Xue Za Zhi. 44:383–389. 2010.(In Chinese).
3	Chen JG and Zhang SW: Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 21:59–69. 2011. View Article : Google Scholar : PubMed/NCBI
4	Luo RH, Zhao ZX, Zhou XY, Gao ZL and Yao JL: Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol. 11:4431–4434. 2005.PubMed/NCBI
5	Groopman JD, Johnson D and Kensler TW: Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. Cancer Biomark. 1:5–14. 2005.PubMed/NCBI
6	Chen TH, Chen CJ, Yen MF, et al: Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 98:257–261. 2002. View Article : Google Scholar : PubMed/NCBI
7	Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ducasse M and Brown MA: Epigenetic aberrations and cancer. Mol Cancer. 5:602006. View Article : Google Scholar
9	Dolinoy DC, Weidman JR and Jirtle RL: Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod Toxicol. 23:297–307. 2007. View Article : Google Scholar : PubMed/NCBI
10	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar
11	Jenuwein T: The epigenetic magic of histone lysine methylation. FEBS J. 273:3121–3135. 2006. View Article : Google Scholar : PubMed/NCBI
12	Barkess G: Chromatin remodeling and genome stability. Genome Biol. 7:3192006. View Article : Google Scholar : PubMed/NCBI
13	Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 8:286–298. 2007. View Article : Google Scholar : PubMed/NCBI
14	Vucic EA, Brown CJ and Lam WL: Epigenetics of cancer progression. Pharmacogenomics. 9:215–234. 2008. View Article : Google Scholar
15	Kouzarides T: Chromatin modifications and their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
16	Dannenberg LO and Edenberg HJ: Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics. 7:1812006. View Article : Google Scholar : PubMed/NCBI
17	R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2008
18	Davis S and Meltzer PS: GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
19	Diboun I, Wernisch L, Orengo C and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
20	Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:2004.PubMed/NCBI
21	Ashburner M, Ball CA, Blake JA, et al: Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
22	Zheng Q and Wang XJ: GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis. Nucleic Acids Res. 36:W358–W363. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kelder T, van Iersel MP, Hanspers K, et al: WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 40:D1301–D1307. 2012. View Article : Google Scholar : PubMed/NCBI
24	Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR and Evelo C: WikiPathways: pathway editing for the people. PLoS Biol. 6:e1842008. View Article : Google Scholar : PubMed/NCBI
25	Zhang B, Kirov S and Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33:W741–W748. 2005. View Article : Google Scholar : PubMed/NCBI
26	Duncan D, Prodduturi N and Zhang B: WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. BMC Bioinformatics. 11(Suppl 4): P102010. View Article : Google Scholar
27	Jeanes A, Gottardi CJ and Yap AS: Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI
28	Do N, Zhao R, Ray K, et al: BMP4 is a novel paracrine inhibitor of liver regeneration. Am J Physiol Gastrointest Liver Physiol. 303:G1220–G1227. 2012. View Article : Google Scholar : PubMed/NCBI
29	Xia Y, Babitt JL, Sidis Y, Chung RT and Lin HY: Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 111:5195–5204. 2008. View Article : Google Scholar : PubMed/NCBI
30	Giannelli G, Mazzocca A, Fransvea E, Lahn M and Antonaci S: Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta. 1815:214–223. 2011.
31	Ikushima H and Miyazono K: TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer. 10:415–424. 2010.
32	Mackay F, Sierro F, Grey ST and Gordon TP: The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun. 8:243–265. 2005. View Article : Google Scholar : PubMed/NCBI
33	Jablonska E, Slodczyk B, Wawrusiewicz-Kurylonek N, et al: Overexpression of B cell-activating factor (BAFF) in neutrophils of oral cavity cancer patients-preliminary study. Neoplasma. 58:211–216. 2011. View Article : Google Scholar : PubMed/NCBI
34	Fragioudaki M, Tsirakis G, Pappa CA, et al: Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leuk Res. 36:1004–1008. 2012. View Article : Google Scholar : PubMed/NCBI
35	Brown KA, Samarajeewa NU and Simpson ER: Endocrine-related cancers and the role of AMPK. Mol Cell Endocrinol. 366:170–179. 2013. View Article : Google Scholar : PubMed/NCBI
36	Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 11:S44–S51. 2001.PubMed/NCBI
37	de Jong FA, de Jonge MJ, Verweij J and Mathijssen RH: Role of pharmacogenetics in irinotecan therapy. Cancer Lett. 234:90–106. 2006.PubMed/NCBI
38	Taves MD, Gomez-Sanchez CE and Soma KK: Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am J Physiol Endocrinol Metab. 301:E11–E24. 2011. View Article : Google Scholar : PubMed/NCBI
39	Rose AJ, Vegiopoulos A and Herzig S: Role of glucocorticoids and the glucocorticoid receptor in metabolism: insights from genetic manipulations. J Steroid Biochem Mol Biol. 122:10–20. 2010. View Article : Google Scholar : PubMed/NCBI
40	Amsterdam A, Tajima K and Sasson R: Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol. 64:843–850. 2002. View Article : Google Scholar : PubMed/NCBI
41	Goldman DC, Bailey AS, Pfaffle DL, Al Masri A, Christian JL and Fleming WH: BMP4 regulates the hematopoietic stem cell niche. Blood. 114:4393–4401. 2009. View Article : Google Scholar : PubMed/NCBI